0001437749-24-020087 | 10-Q | XBRL Viewer | Streamline Health Solutions INC

Note 9 - Related Party Transactions

3 Months Ended

Apr. 30, 2024

NOTE 9 - RELATED PARTY TRANSACTIONS

Avelead Office Lease

The Company acquired Avelead on August 16, 2021. Accordingly, the Company assumed a lease for corporate office space from one of the selling shareholders of Avelead who was employed by the company through August 2023. This lease term ended February 2023. For the three months ended April 30, 2024 and 2023, the Company recorded rent expense of $0 and $6,000, respectively. Refer to Note 3 – Business Combination for additional information.

Debt Private Placement

On February 1, 2024, the Company entered into a securities purchase agreement with certain accredited investors, including certain directors and officers of the Company (collectively, the “Investors”), pursuant to which the Company agreed to sell to the Investors unsecured subordinated promissory notes in the aggregate principal amount of $4.4 million and warrants to purchase up to an aggregate of 4,016,025 shares of the Company’s common stock in a private placement (the “Debt Private Placement”). The closing of the Debt Private Placement occurred on February 7, 2024. Refer to Note 5 – Debt for additional information. The following related parties participated in the Debt Private Placement:

Name of Investor	Investment Amount		Warrants Granted
121G, LLC (1)	$	1,000,000		897,436
Matthew Etheridge (2)		1,000,000		921,053
Jonathan R. Phillips (3)		50,000		44,872
The Ferayorni Family Trust (4)		500,000		448,718

(1) The securities held in the account of 121G, LLC (“121G”) may be deemed to be beneficially owned by Wyche “Tee” Green, III, the managing member of 121G. Mr. Green serves as Executive Chairman of the Company and is a member of the Company’s Board of Directors.

(2) Mr. Etheridge became a member of the Company’s Board of Directors subsequent to the closing of the Debt Private Placement.
(3) Mr. Phillips is a member of the Company’s Board of Directors.
(4) The securities held in the account of The Ferayorni Family Trust may be deemed to be beneficially owned by Justin J. Ferayorni as co-trustee of The Ferayorni Family Trust. Mr. Ferayorni is a member of the Company’s board of directors.

Common Stock Private Placement

On February 6, 2024, the Company completed the sale of 263,158 shares of the Company’s common stock to Matthew Etheridge at a purchase price of $0.38 per share for an aggregate purchase price of $100,000. Mr. Etheridge became a director of the Company subsequent to the closing of the Debt Private Placement.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Note 6 - Income Taxes (Details Textual) - USD ($)	3 Months Ended
Note 6 - Income Taxes (Details Textual) - USD ($)	Apr. 30, 2024	Apr. 30, 2023	Jan. 31, 2024
Income Tax Expense (Benefit)	$ (0)	$ 53,000
Effective Income Tax Rate Reconciliation, Percent	0.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	24.00%
Unrecognized Tax Benefits	$ 346,000		$ 340,000

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Note 5 - Debt (Details Textual)		3 Months Ended
Note 5 - Debt (Details Textual)	Nov. 29, 2022 USD ($)	Apr. 30, 2024 USD ($) $ / shares	May 24, 2024 shares	Feb. 07, 2024 USD ($)	Feb. 01, 2024 USD ($) shares	Jan. 31, 2024 USD ($)
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	Prime Rate [Member]	Prime Rate [Member]
Common Stock Warrant [Member]
Derivative Liability				$ 881,000	$ 881,000
Professional Fees		$ 46,000
Maximum [Member]
Common Stock, Shares, Outstanding, Percent		9.99%
Non Directors and Officers [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares		$ 0.38
Directors and Officers [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares		$ 0.39
Securities Purchase Agreement February 2024 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares					4,016,025
Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member] \| Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares			4,016,025
Term Loan [Member]
Debt Instrument, Basis Spread on Variable Rate	1.50%
Debt Instrument, Basis Rate Floor	3.25%
Debt Instrument, Face Amount	$ 10,000,000
Debt Instrument, Term (Year)	5 years
Long-Term Debt, Maturity, Year Two		$ 500,000
Long-Term Debt, Maturity, Year Three		1,000,000
Long-Term Debt, Maturity, Year Four		2,000,000
Long-Term Debt, Maturity, Year Five		$ 3,000,000
Term Loan and Revolving Line of Credit [Member]
Debt Instrument, Basis Spread on Variable Rate		1.50%
Debt Instrument, Basis Rate Floor		3.25%
Debt Instrument, Covenant, Fixed Charge Coverage Ratio		1.2
Amortization of Debt Issuance Costs		$ 250,000
Debt Instrument, Fair Value Disclosure		8,560,000				$ 8,807,000
Debt Instrument, Unamortized Discount		190,000				$ 193,000
Unsecured Subordinated Promissory Notes [Member]
Debt Instrument, Face Amount		4,400,000
Debt Instrument, Interest Rate, Effective Percentage					15.00%
Debt Instrument, Fair Value Disclosure		3,538,000
Debt Instrument, Unamortized Discount		862,000
Debt Issuance Costs, Gross		$ 183,000
Unsecured Subordinated Promissory Notes [Member] \| Securities Purchase Agreement February 2024 [Member]
Debt Instrument, Face Amount					$ 4,400,000
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,000,000
Debt Instrument, Basis Spread on Variable Rate	1.50%
Debt Instrument, Basis Rate Floor	3.25%

Note 1 - Basis of Presentation

3 Months Ended

Apr. 30, 2024

Notes to Financial Statements

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]

NOTE 1 — BASIS OF PRESENTATION

Streamline Health Solutions, Inc. and each of its wholly-owned subsidiaries, Streamline Health, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Streamline Pay & Benefits, LLC, (collectively, unless the context requires otherwise, “we,” “us,” “our,” “Streamline,” or the “Company”), operate in one segment as a provider of healthcare information technology solutions and associated services. The Company provides these capabilities through the licensing of its Coding & Clinical Documentation Improvement (CDI) solutions, eValuator coding analysis platform, RevID, and other workflow software applications and the use of such applications by software as a service (“SaaS”). The Company also provides audit services to help clients optimize their internal clinical documentation and coding functions, as well as implementation and consulting services to complement its software solutions. The Company’s software and services enable hospitals and integrated healthcare delivery systems in the United States and Canada to capture, store, manage, route, retrieve and process patient clinical, financial and other healthcare provider information related to the patient revenue cycle.

The accompanying unaudited condensed consolidated financial statements have been prepared by us pursuant to the rules and regulations applicable to quarterly reports on Form 10-Q of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. The condensed consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and each of its wholly-owned subsidiaries. In the opinion of the Company’s management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s most recent annual report on Form 10-K. Operating results for the three months ended April 30, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending January 31, 2025.

The Company has one operating segment and one reporting unit due to the singular nature of our products, product development and distribution process, and client base as a provider of computer software-based solutions and services for acute-care healthcare providers.

All amounts in the condensed consolidated financial statements, notes and tables have been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated. All references to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following calendar year.

Note 8 - Commitments and Contingencies

3 Months Ended

Apr. 30, 2024

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

NOTE 8 — COMMITMENTS AND CONTINGENCIES

Consulting Agreement with 180 Consulting, LLC

On March 19, 2020, the Company entered into a Master Services Agreement (the “MSA”) with 180 Consulting, pursuant to which 180 Consulting has provided and will continue to provide a variety of consulting services in support of eValuator products including product management, operational consulting, staff augmentation, internal systems platform integration and software engineering services, among others, through separate executed statements of work (“SOWs”). On September 20, 2021, the Company entered into a separate MSA in support of Avelead products. As of December 2023, all outstanding SOWs under both MSAs were effectively replaced by two new SOWs. As of April 30, 2024, there were three active SOWs under the eValuator MSA. One of the active SOWs includes the ability to earn stock at a conversion rate to be calculated 20 days after the execution of the related SOW. The MSA includes a termination clause upon a 90-day written notice. While no related party has a direct or indirect material interest in this MSA or the related SOWs, individuals providing services to the Company under the MSA and the SOWs may share workspace and administrative costs with 121G Consulting, LLC (“121G”). Mr. Green is a “member” of 121G, and, accordingly, has a financial interest in that entity. 180 Consulting earned 418,653 and 127,099 shares for the three months ended April 30, 2024 and 2023, respectively, and has earned an aggregate of 1,898,560 shares of the Company’s common stock through April 30, 2024. For services rendered by 180 Consulting during the three months ended April 30, 2024 and 2023, the Company incurred fees of $539,000 and $953,000, respectively, and capitalized non-employee stock compensation of $30,000 and $23,000, respectively. The Company paid fees of $376,000 and $452,000 for services rendered by 180 Consulting during the three months ended April 30, 2024 and 2023, respectively.

Inclusive of the MSA executed with 180 Consulting are SOWs that provide for the Company to sublicense software through 180 Consulting that is owned by 121G. This is a services agreement for access to software that assists the Company in implementing and integrating with our clients’ technology. The license agreement is designed such that there is no material financial benefit that accrues to 121G. 180 Consulting licenses the software from 121G at cost. The Company paid approximately $141,000 and $117,000 for the SOWs that include the sublicense agreement for the three months ended April 30, 2024 and 2023, respectively, which are included in the aforementioned totals above.

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Total revenues	$ 4,330,000	$ 5,332,000
Transferred over Time [Member]
Total revenues	4,195,000	5,258,000
Transferred at Point in Time [Member]
Total revenues	$ 135,000	$ 74,000

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Apr. 30, 2024	Jan. 31, 2024
Current assets:
Cash and cash equivalents	$ 3,979,000	$ 3,190,000
Accounts receivable, net of allowance for credit losses of $117,000 and $86,000, respectively	4,706,000	4,237,000
Contract receivables	294,000	780,000
Prepaid and other current assets	722,000	629,000
Total current assets	9,701,000	8,836,000
Non-current assets:
Property and equipment, net of accumulated amortization of $304,000 and $291,000 respectively	76,000	88,000
Capitalized software development costs, net of accumulated amortization of $8,396,000 and $7,960,000, respectively	5,624,000	5,798,000
Intangible assets, net of accumulated amortization of $4,428,000 and $4,019,000, respectively	11,662,000	12,071,000
Goodwill	13,276,000	13,276,000
Other	1,386,000	1,666,000
Total non-current assets	32,024,000	32,899,000
Total assets	41,725,000	41,735,000
Current liabilities:
Accounts payable	1,120,000	1,253,000
Accrued expenses	1,777,000	2,023,000
Current portion of term loan	1,750,000	1,500,000
Deferred revenues	7,351,000	7,112,000
Acquisition earnout liability	817,000	1,794,000
Total current liabilities	12,815,000	13,682,000
Non-current liabilities:
Term loan, net of current portion and deferred financing costs	7,089,000	7,566,000
Line of credit	0	1,500,000
Non-current portion of notes payable	3,587,000	0
Warrants – common stock	746,000	0
Deferred revenues, less current portion	185,000	173,000
Total non-current liabilities	11,607,000	9,239,000
Total liabilities	24,422,000	22,921,000
Stockholders’ equity:
Common stock, $0.01 par value per share, 85,000,000 shares authorized; 61,825,587 and 58,945,498 shares issued and outstanding, respectively	617,000	590,000
Additional paid in capital	135,124,000	133,923,000
Accumulated deficit	(118,438,000)	(115,699,000)
Total stockholders’ equity	17,303,000	18,814,000
Total liabilities and stockholders’ equity	$ 41,725,000	$ 41,735,000

Note 5 - Debt (Tables)

3 Months Ended

Apr. 30, 2024

Notes Tables

Schedule of Debt [Table Text Block]

	April 30, 2024			January 31, 2024
Term loan	$	8,750,000		$	9,000,000
Financing cost payable		150,000			135,000
Less: Deferred financing cost		(61,000	)		(69,000	)
Total		8,839,000			9,066,000
Less: Current portion of term loan		(1,750,000	)		(1,500,000	)
Non-current portion of term loan	$	7,089,000		$	7,566,000

	April 30, 2024			January 31, 2024
Notes payable	$	4,552,000		$	—
Less: Discount on notes payable		(796,000	)		—
Less: Deferred financing costs		(169,000	)		—
Total		3,587,000			—
Less: Current portion of notes payable		—			—
Non-current portion of notes payable	$	3,587,000		$	—

Schedule Of Minimum Adjusted EBITDA [Table Text Block]

	Minimum
Quarter Ending	Adjusted EBITDA
January 31, 2024	$	(5,750,000	)
April 30, 2024		(4,560,000	)
July 31, 2024		(2,960,000	)
October 31, 2024		(1,500,000	)
January 31, 2025		430,000

Schedule of Debt to APR Ratios [Table Text Block]

	Maximum
	ARR Net Leverage
Quarter Ending	Ratio
April 30, 2024	0.50	to	1.00
July 31, 2024	0.45	to	1.00
October 31, 2024	0.40	to	1.00
January 31, 2025	0.35	to	1.00

Schedule of Debt, Adjusted EBITDA [Table Text Block]

	Maximum
	Debt to Adjusted
	EBITDA
Quarter Ending	Ratio
April 30, 2025	3.50	to	1.00
July 31, 2025	3.00	to	1.00
October 31, 2025	2.50	to	1.00
January 31, 2026 and on the last day of each quarter thereafter	2.00	to	1.00

Note 5 - Debt - Schedule of Adjusted EBITDA Ratio (Details) - Forecast [Member]	3 Months Ended
	Jan. 31, 2026	Oct. 31, 2025	Jul. 31, 2025	Apr. 30, 2025
Maximum [Member]
Adjusted EBITDA ratio	2	2.5	3	3.5
Minimum [Member]
Adjusted EBITDA ratio	1	1	1	1

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member] Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	0
Balance (in shares) at Jan. 31, 2023					57,567,210
Balance (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	$ 0	$ 0	$ 36,000	$ 36,000
Balance at Jan. 31, 2023					$ 576,000	$ 131,973,000	$ (97,038,000)	$ 35,511,000
Restricted stock issued (in shares)					1,185,927
Restricted stock issued					$ 12,000	(12,000)	0	0
Restricted stock forfeited (in shares)					(28,400)
Restricted stock forfeited					$ (1,000)	(1,000)	0	0
Surrender of shares (in shares)					(88,326)
Surrender of shares					$ (1,000)	(178,000)	0	(179,000)
Share-based compensation					0	595,000	0	595,000
Net loss					$ 0	0	(2,901,000)	(2,901,000)
Balance (in shares) at Apr. 30, 2023					58,636,411
Balance at Apr. 30, 2023					$ 586,000	132,379,000	(99,903,000)	33,062,000
Balance (in shares) at Jan. 31, 2024					58,945,498
Balance at Jan. 31, 2024					$ 590,000	133,923,000	(115,699,000)	18,814,000
Restricted stock issued (in shares)					1,215,000
Restricted stock issued					$ 11,000	(11,000)	0	0
Restricted stock forfeited (in shares)					(48,350)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(139,105)
Surrender of shares					$ (1,000)	(66,000)	0	(67,000)
Share-based compensation					$ 0	529,000	0	529,000
Issuance of common stock (in shares)					1,852,544
Issuance of common stock					$ 17,000	753,000	0	770,000
Offering expenses					0	(4,000)	0	(4,000)
Net loss					$ 0	0	(2,739,000)	(2,739,000)
Balance (in shares) at Apr. 30, 2024					61,825,587
Balance at Apr. 30, 2024					$ 617,000	$ 135,124,000	$ (118,438,000)	$ 17,303,000

Note 5 - Debt - Schedule of Minimum Adjusted EBITDA (Details) - USD ($)	Jan. 31, 2025	Oct. 31, 2024	Jul. 31, 2024	Apr. 30, 2024	Jan. 31, 2024
Minimum Adjusted EBITDA				$ (4,560,000)	$ (5,750,000)
Forecast [Member]
Minimum Adjusted EBITDA	$ 430,000	$ (1,500,000)	$ (2,960,000)

Significant Accounting Policies (Policies)

3 Months Ended

Apr. 30, 2024

Accounting Policies [Abstract]

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates.

Reclassification, Comparability Adjustment [Policy Text Block]

Reclassification

Certain amounts for the three months ended April 30, 2023, were reclassified to conform to the current period classification. For the three months ended April 30, 2023, the Company incurred acquisition-related costs totaling $35,000, consisting primarily of professional service fees. The aforementioned acquisition-related costs for the three months ended April 30, 2023, were previously presented in a separate, single caption and are now included in selling, general, and administrative expense in the accompanying condensed consolidated statements of operations, which is consistent with the presentation for the current period.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

The Financial Accounting Standards Board’s (“FASB”) authoritative guidance on fair value measurements establishes a framework for measuring fair value. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The acquisition earnout liability transferred out of Level 3 as of three months ended April 30, 2024.

The table below provides information on the fair value of our liabilities:

			Quoted		Significant
			Prices in		Other		Significant
			Active		Observable		Unobservable
	*Total Fair*		*Markets*		*Inputs*		*Inputs*
	*Value*		*(Level 1)*		*(Level 2)*		*(Level 3)*
At January 31, 2024
Acquisition earnout liability (1)	$	1,794,000	$	—	$	—	$	1,794,000
At April 30, 2024
Warrants - common stock (2)	$	746,000	$	—	$	746,000	$	—

(1)

On March 27, 2024, the Company issued the shares of its common stock owed as part of the acquisition earnout liability related to the acquisition of Avelead Consulting, LLC (“Avelead”). The remaining obligation related to the acquisition earnout liability is to be settled in cash (refer to Note 3 – Business Combinations for more information). At that time, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was removed from the hierarchy. As of that date, the Company recorded a valuation adjustment of $159,000 using the value of the shares issued adjusted for a discount for lack of marketability. As of April 30, 2024, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was transferred out. See the table below for the roll-forward of values including the amount transitioned out of Level 3.

(2)

The fair value of the common stock warrants issued in connection with the Company’s equity raises in February 2024 is established as of the date of issuance and updated as of April 30, 2024. The change in the fair value of the common stock warrants decreased by $135,000 from its initial measurement date on February 7, 2024 through April 30, 2024. The change in the fair value is recognized in “valuation adjustments” in the accompanying condensed consolidated statement of operations.

The estimated fair value of the warrant liability is calculated using a Black-Scholes pricing model. The model input uses the warrant strike pries of $0.38 and $0.39, market prices on the measurement dates ($0.34 as of February 7, 2024 and $0.30 as of April 30, 2024) plus assumptions for expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). The warrants carry a term of 48 months and the Company assumes they are held until expiration. The risk-free rate was determined from the U.S. Treasury published daily treasury yields corresponding with the remaining expected term which ranged between 4% - 5%. The Company’s common stock volatility was estimated between 91% - 92% utilizing its historical average closing price for preceding trading days equal to expected term remaining. Fluctuations in the risk-free rate of interest or the Company’s stock price could have a material impact on reported expenses.

The table below provides the Level 3 roll-forward on the fair value of our acquisition earnout liability for the three months ended April 30, 2024:

	3 months ended
	04/30/2024
Beginning balance	$	1,794,000
Settlement – common stock		(690,000	)
Settlement – cash		(447,000	)
Unrealized loss		159,000
Transfer out		(817,000	)
Ending balance	$	—
Amount of unrealized loss for the period included in income relating to the acquisition earnout liability at the end of the period	$	(159,000	)

The value of the Company’s acquisition earnout liability at April 30, 2024 represents the remaining cash obligation of $817,000. The Company reached an agreement with the former owners of Avelead to settle the cash obligation by making periodic payments through October 31, 2024.

The fair value of the Company’s term loan and outstanding balance of the revolving line of credit under its Second Amended and Restated Loan and Security Agreement (as amended and modified, the “Second Amended and Restated Loan Agreement”) was determined through an analysis of the interest rate spread from the date of closing the loan ( August 2021) to the date of the most recent balance sheets, April 30, 2024 and January 31, 2024. The term loan bears interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus 1.5%, with a Prime “floor” rate of 3.25%. The prime rate is variable and, thus accommodates changes in the market interest rate. However, the interest rate spread (the 1.5% added to the Prime Rate) is fixed. We estimated the impact of the changes in the interest rate spread by analogizing the effect of the change in the published “Corporate Bond Rates,” reduced for any changes in the market interest rate. This provided us with an estimated change to the interest rate spread of approximately 0.5% from (i) the date we entered the Second Amended and Restated Loan Agreement for the term loan or (ii) the date of each draw on the revolving line of credit to the end of the fiscal third quarter, October 31, 2023, and end of the fiscal year, January 31, 2024. The fair value of the debt as of April 30, 2024 and January 31, 2024 was estimated to be $8,560,000 and $8,807,000, respectively, or a discount to book value of $190,000 and $193,000, respectively.

Revenue [Policy Text Block]

Revenue Recognition

We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model, through the Company’s direct sales force or through third-party resellers. Licensed, locally-installed customers on a perpetual model utilize the Company’s support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization of the applications, as well as audit services and consulting services.

We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, under the core principle of recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

Disaggregation of Revenue

The following table provides information about disaggregated revenue by type and nature of revenue stream:

	Three Months Ended
	April 30, 2024		April 30, 2023
Over time revenue	$	4,195,000	$	5,258,000
Point in time revenue		135,000		74,000
Total revenue	$	4,330,000	$	5,332,000

The Company includes revenue categories of (i) over time and (ii) point in time revenue. The Company includes revenue categories of (i) SaaS, (ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses as point in time revenue.

Contract Receivables and Deferred Revenues

The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. The Company’s contract receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. During the three months ended April 30, 2024, the Company recognized approximately $2,831,000 in revenue from deferred revenues outstanding as of January 31, 2024. Revenue allocated to remaining performance obligations was $29,143,000 as of April 30, 2024, of which the Company expects to recognize approximately 45% over the next 12 months and the remainder thereafter.

Deferred costs (costs to fulfill a contract and contract acquisition costs)

The Company defers the direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill a contract. These deferred costs will be amortized on a straight-line basis over the period of expected benefit which is the contractual term. As of April 30, 2024 and January 31, 2024, the Company had deferred costs of $65,000 and $77,000, respectively, net of accumulated amortization of $123,000 and $102,000, respectively. Amortization expense of these costs was $20,000 and $18,000 for the three months ended April 30, 2024 and 2023, respectively, and is included in cost of SaaS in the condensed consolidated statements of operations.

Contract acquisition costs, which consist of sales commissions paid or payable, are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs is expected to be one year or less.

As of April 30, 2024 and January 31, 2024, deferred commission costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $1,321,000 and $1,461,000, respectively. Amortization expense associated with deferred sales commissions, which is included in selling, general and administrative expense in the condensed consolidated statements of operations, was $140,000 and $129,000 for the three months ended April 30, 2024 and 2023, respectively.

Allowance for Credit Losses

The Company estimates current expected credit losses based on historical credit loss rates and applied an increase to account for future economic conditions. The changes in the Company’s allowance for credit losses is as follows:

		January 31, 2024				CECL Adoption				Provision adjustments				Write-offs & Recoveries				April 30, 2024
Allowance for credit losses		$	86,000			$	—			$	—			$	31,000			$	117,000

		January 31, 2023				CECL Adoption				Provision adjustments				Write-offs & Recoveries				April 30, 2023
Allowance for credit losses		$	132,000			$	(36,000	)		$	—			$	—			$	96,000

Share-Based Payment Arrangement [Policy Text Block]

Equity Awards

The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite service period, and forfeitures are recognized as incurred. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the entity had paid cash for the goods or services. The Company incurred total compensation expense related to share-based awards for the three months ended April 30, 2024 and 2023, of $499,000 and $572,000 respectively, net of $30,000 and $23,000 of capitalized non-employee stock compensation, respectively.

The fair value of stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). Future grants of equity awards accounted for as share-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards.

The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market closing price per share on the grant date. For the three months ended April 30, 2024 and 2023, the Company issued 1,015,000 and 1,085,000 shares of restricted common stock to employees, respectively. The Company expenses the compensation cost of these awards as the restriction period lapses, which is typically over a three-year period. For the three months ended April 30, 2024, the Company issued 200,000 shares of restricted common stock to certain members of the Board of Directors. There were no shares issued to the Board of Directors in the three months ended April 30, 2023.

Derivatives, Policy [Policy Text Block]

Warrants

The Company reviews the specific terms for its warrants and applies the authoritative FASB guidance under ASC topics 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”) to account for the warrants as either equity-classified or liability-classified instruments. This review identifies if the warrants are freestanding financial instruments under ASC 480, should be defined as a liability under ASC 480, and whether the warrants meet all requirements of ASC 815 to be classified as equity, including whether the warrants are indexed to the Company’s own common stock, if there are conditions where warrant holders could potentially require “net cash settlement” in a circumstance that would be outside of the Company’s control, among other conditions for equity classification. This assessment requires the use of professional judgment and is conducted at the time of warrant issuance plus as of each subsequent quarterly period end date while the warrants are outstanding.

For the issued or modified warrants that qualify for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed consolidated Statements of Operations as "valuation adjustments." The fair value of the warrants is estimated using a Black-Scholes pricing model.

The Company issued warrants to purchase shares of common stock as part of the Securities Purchase Agreement. Based on the previously noted guidance, the Company determined that warrants issued in with the Securities Purchase Agreement should be recorded and accounted for as a liability as of April 30, 2024. The Company reports the fair value of the liability as non-current liabilities under the heading "Warrants – common stock" on the condensed consolidated Balance Sheet. The Company recorded an opening warrant liability of $881,000 as of February 7, 2024, with a subsequent $135,000 gain recorded under "Valuation adjustments" on the condensed consolidated Statement of Operations as of April 30, 2024. The Company will reassess this classification and re-measure at each balance sheet date, as necessary.

Income Tax, Policy [Policy Text Block]

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. Refer to Note 6 – Income Taxes for further details.

The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. The Company believes it has appropriately accounted for any uncertain tax positions as of April 30, 2024.

Earnings Per Share, Policy [Policy Text Block]

Net Loss Per Common Share

The Company presents basic and diluted earnings per share (“EPS”) data for the Company’s common stock.

The Company’s warrants, unvested restricted stock awards, and options are considered non-participating securities because holders are not entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term or while unexercised. Diluted EPS for the Company’s common stock is computed using the treasury stock method.

The following is the calculation of the basic and diluted net loss per share of common stock for the three months ended April 30, 2024 and 2023:

	Three Months Ended
	April 30, 2024			April 30, 2023
Basic and diluted loss per share:
Net loss	$	(2,739,000	)	$	(2,901,000	)
Basic and diluted net loss per share of common stock	$	(0.05	)	$	(0.05	)
Weighted average shares outstanding – basic and diluted (1)(2)		58,224,090			55,970,880

(1)	Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of April 30, 2024 and 2023, there were 2,687,471 and 2,655,831 unvested restricted shares of common stock outstanding, respectively.

(2)	Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three months ended April 30, 2024, diluted earnings per share excludes 66,000 outstanding stock options, 2,687,471 unvested restricted shares of common stock, and 4,016,025 shares of common stock issuable through the exercise of warrants. For the three months ended April 30, 2023, diluted earnings per share excludes 628,958 outstanding stock options and 2,655,831 unvested restricted shares of common stock.

Noncash Investing and Financing Activities [Policy Text Block]

Non-Cash Items

For the three months ended April 30, 2024 and 2023, the Company recorded a change in capitalized software purchased with stock, totaling $30,000 and $23,000, respectively, as non-cash items as it relates to non-cash investing activities in the condensed consolidated statements of cash flow.

For the three months ended April 30, 2024, the Company settled the second earnout with the issuance of common shares in the amount of $690,000, issued warrants in the amount of $881,000 as debt discounts, deferred financing costs for the Notes (refer to Note 5 – Debt) in the amount of $167,000 which are accrued as of April 30, 2024, and professional fees for the Common Stock Private Placement (refer to Note 7 – Equity) in the amount of $4,000, respectively, as non-cash items as it relates to non-cash financing activities in the condensed consolidated statements of cash flows. The Company did not have any non-cash financing activities in the three months ended April 30, 2023.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements Not Yet Adopted

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves guidance around the disclosures about a public entity’s reportable segments and additional details about a reportable segment’s expenses. ASU 2023-07 is effective for all public entities for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company’s adoption of ASU 2023-07 will be effective in the annual report for the fiscal year ending January 31, 2025. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhance the transparency and decision usefulness of income tax disclosures. For public entities, ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or disclosures.

Note 2 - Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details) - USD ($)

3 Months Ended

Apr. 30, 2024

Apr. 30, 2023

Net loss

$ (2,739,000)

$ (2,901,000)

Net loss per common share – basic and diluted (in dollars per share)

$ (0.05)

Weighted average number of common shares – basic and diluted (in shares)

^[1],[2]

58,224,090

55,970,880

[1]

Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three months ended April 30, 2024, diluted earnings per share excludes 66,000 outstanding stock options, 2,687,471 unvested restricted shares of common stock, and 4,016,025 shares of common stock issuable through the exercise of warrants. For the three months ended April 30, 2023, diluted earnings per share excludes 628,958 outstanding stock options and 2,655,831 unvested restricted shares of common stock.

[2]

Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of April 30, 2024 and 2023, there were 2,687,471 and 2,655,831 unvested restricted shares of common stock outstanding, respectively.

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Note 5 - Debt - Schedule of Outstanding Debt (Details) - USD ($)	Apr. 30, 2024	Jan. 31, 2024
Total	$ 8,839,000	$ 9,066,000
Total	3,587,000	0
Less: Current portion of notes payable	0	0
Non-current portion of notes payable	3,587,000	0
Revolving Credit Facility [Member]
Long term debt, gross	150,000	135,000
Notes payable	150,000	135,000
Term Loan [Member]
Long term debt, gross	8,750,000	9,000,000
Less: Current portion of term loan	(1,750,000)	(1,500,000)
Total non-current portion of debt	7,089,000	7,566,000
Notes payable	8,750,000	9,000,000
Note Payable [Member[
Long term debt, gross	4,552,000	0
Less: Deferred financing cost	(169,000)	0
Notes payable	4,552,000	0
Less: Discount on notes payable	(796,000)	0
Term Loan and Revolving Line of Credit [Member]
Less: Deferred financing cost	(61,000)	(69,000)
Less: Discount on notes payable	$ (190,000)	$ (193,000)

Note 6 - Income Taxes

3 Months Ended

Apr. 30, 2024

Notes to Financial Statements

Income Tax Disclosure [Text Block]

NOTE 6 — INCOME TAXES

Income tax was $0 for the three months ended April 30, 2024, compared to an expense of $53,000 in the prior year comparable period. The effective income tax rate on continuing operations of approximately 0% differs from our combined federal and state statutory rate of 24% primarily due to the full valuation allowance the Company currently maintains on its net deferred tax asset.

The Company has recorded $346,000 and $340,000 in reserves for uncertain tax positions as of April 30, 2024 and January 31, 2024, respectively.

The Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2019. All material state and local income tax matters have been concluded for years through January 31, 2018. The Company is no longer subject to IRS examination for periods prior to the tax year ended January 31, 2019; however, carryforward losses that were generated prior to the tax year ended January 31, 2019, may still be adjusted by the IRS if they are used in a future period.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Note 4 - Operating Leases (Details Textual) - USD ($)	3 Months Ended		18 Months Ended
Note 4 - Operating Leases (Details Textual) - USD ($)	Apr. 30, 2024	Apr. 30, 2023	Mar. 31, 2023	Oct. 01, 2021	Aug. 16, 2021	Mar. 01, 2020
Membership Agreements and Daily Space Rentals [Member]
Operating Lease, Expense	$ 7,000	$ 4,000
Alpharetta Sublease [Member]
Lessor, Operating Lease, Term of Contract (Month)				18 months
Sublease Income	0	32,000	$ 292,000
Alpharetta Office Lease [Member]
Operating Lease, Right-of-Use Asset						$ 540,000
Lessee, Operating Lease, Discount Rate						6.50%
Operating Lease, Cost	0	32,000
Suwanee Office Lease [Member]
Operating Lease, Expense	$ 0	$ 6,000
Lessee, Operating Lease, Term of Contract (Month)					36 months
Lessee, Operating Lease, Renewal Term (Month)					12 months

Unaudited Condensed Consolidated Statements of Operations - USD ($)

3 Months Ended

Apr. 30, 2024

Apr. 30, 2023

Revenues:

Total revenues

$ 4,330,000

$ 5,332,000

Operating expenses:

Selling, general and administrative expense

3,192,000

3,841,000

Research and development

1,111,000

1,701,000

Total operating expenses

6,580,000

8,328,000

Operating loss

(2,250,000)

(2,996,000)

Other (expense) income:

Interest expense

(465,000)

(248,000)

Valuation adjustments

(24,000)

364,000

Other

32,000

Loss before income taxes

(2,739,000)

(2,848,000)

Income tax expense

(53,000)

Net loss

$ (2,739,000)

$ (2,901,000)

Basic and Diluted Earnings Per Share:

Net loss per common share – basic and diluted (in dollars per share)

$ (0.05)

Weighted average number of common shares – basic and diluted (in shares)

^[1],[2]

58,224,090

55,970,880

Software as a Service [Member]

Revenues:

Total revenues

$ 2,723,000

$ 3,175,000

Operating expenses:

Cost of goods and services

1,348,000

1,589,000

Maintenance [Member]

Revenues:

Total revenues

890,000

1,157,000

Operating expenses:

Cost of goods and services

42,000

89,000

Professional Fees and Licenses [Member]

Revenues:

Total revenues

717,000

1,000,000

Operating expenses:

Cost of goods and services

$ 887,000

$ 1,108,000

[1]

[2]

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Apr. 30, 2024	Jan. 31, 2024
Allowance for credit losses	$ 117,000	$ 86,000
Accumulated amortization	304,000	291,000
Capitalized software accumulated amortization	8,396,000	7,960,000
Intangible assets, accumulated amortization	$ 4,428,000	$ 4,019,000

Note 2 - Summary of Significant Accounting Policies - Fair Value of Liabilities (Details) - USD ($)

Apr. 30, 2024

Jan. 31, 2024

Acquisition earnout liability (1)

^[1]

$ 1,794,000

Common Stock Warrant [Member]

Warrants - common stock (2)

^[2]

$ 746,000

Fair Value, Inputs, Level 1 [Member]

Acquisition earnout liability (1)

^[1]

Fair Value, Inputs, Level 1 [Member] | Common Stock Warrant [Member]

Warrants - common stock (2)

^[2]

Fair Value, Inputs, Level 2 [Member]

Acquisition earnout liability (1)

^[1]

Fair Value, Inputs, Level 2 [Member] | Common Stock Warrant [Member]

Warrants - common stock (2)

^[2]

746,000

Fair Value, Inputs, Level 3 [Member]

Acquisition earnout liability (1)

^[1]

$ 1,794,000

Fair Value, Inputs, Level 3 [Member] | Common Stock Warrant [Member]

Warrants - common stock (2)

^[2]

$ 0

[1]

On March 27, 2024, the Company issued the shares of its common stock owed as part of the acquisition earnout liability. The remaining obligation related is to be settled in cash (refer to Note 3 - Business Combinations for more information). At that time, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was removed from the hierarchy. On that date, the Company used a probability-weighted discounted cash flow using a Monte Carlo valuation method to determine the remaining value of the liability for the cash obligation. As of April 30, 2024, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was transferred out. See the table below for the roll-forward of values including the amount transitioned out of Level 3. The probability-weighted discounted cash flow is calculated using a Monte Carlo valuation method. The valuation model provides numerous outcomes. The outcomes are averaged and discounted to present value, which provides the current value point estimate. A range of possible outcomes is not available under the specific valuation method that was used in determining fair value of the acquisition earnout liability. The significant inputs include recorded Avelead SaaS revenue, the probabilities associated with each of (i) a change in control or (ii) a certain client termination, as well as other normal and customary inputs to financial models, including but not limited to, risk factors and interest rates.

[2]

The fair value of the common stock warrants issued in connection with the Company's equity raises in February 2024 is established as of the date of issuance and updated as of April 30, 2024. The change in the fair value of the common stock warrants decreased by $135,000 from its initial measurement date on February7, 2024 through April 30, 2024. The change in the fair value is recognized in “valuation adjustments” in the accompanying condensed consolidated statement of operations. The estimated fair value of the warrant liability is calculated using a Black-Scholes pricing model. The model input uses the warrant strike pries of $0.38 and $0.39, market prices on the measurement dates ($0.34 as of February 7, 2024 and $0.30 as of April 30, 2024) plus assumptions for expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). The warrants carry a term of 48 months and the Company assumes they are held until expiration. The risk-free rate was determined from the U.S. Treasury published daily treasury yields corresponding with the remaining expected term which ranged between 4% - 5%. The Company's common stock volatility was estimated between 91% - 92% utilizing its historical average closing price for preceding trading days equal to expected term remaining. Fluctuations in the risk-free rate of interest or the Company’s stock price could have a material impact on reported expenses The estimated fair value of the warrant liability is calculated using a Black-Scholes pricing model. The model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). Fluctuations in the risk-free rate of interest or the Company’s stock price could have a material impact on reported expenses.

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column E))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483466/210-20-50-3

Reference 28: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483444/210-20-55-22

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483444/210-20-55-10

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-10

+ Details

Note 3 - Business Combination (Details Textual) - USD ($)

3 Months Ended

Mar. 27, 2024

Apr. 30, 2024

Jan. 31, 2024

Business Combination, Contingent Consideration, Liability

^[1]

$ 1,794,000

Business Combination, Contingent Consideration, Liability, Current

$ 817,000

1,794,000

Avelead Acquisition [Member]

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)

1,589,386

Common Stock, Par or Stated Value Per Share (in dollars per share)

$ 0.01

Payments to Acquire Businesses, Gross

447,000

Business Combination, Contingent Consideration, Liability, Current

$ 817,000

Avelead Acquisition [Member] | Earn Out Liability [Member]

Business Combination, Contingent Consideration, Liability

$ 1,794,000

[1]

Note 8 - Commitments and Contingencies (Details Textual) - Master Services Agreement [Member] - 180 Consulting [Member] - USD ($)	3 Months Ended		49 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024
Stock Issued During Period, Shares, Issued for Services (in shares)	418,653	127,099	1,898,560
Professional Fees	$ 539,000	$ 953,000
Share-Based Payment Arrangement, Amount Capitalized	30,000	23,000
Payments for Other Fees	376,000	452,000
Statements of Work Under Sublease [Member]
Payments for Other Fees	$ 141,000	$ 117,000

Note 2 - Summary of Significant Accounting Policies - Schedule of Restructuring Information (Details) $ in Thousands	3 Months Ended
	Apr. 30, 2024 USD ($)
Restructuring reserve	$ 74
Restructuring charges	0
Restructuring payments	(65)
Restructuring reserve	9
Restructuring costs incurred	759
Expected restructuring costs	759
Employee Severance Allocated to Cost of Sales [Member]
Restructuring reserve	0
Restructuring charges	0
Restructuring payments	0
Restructuring reserve	0
Restructuring costs incurred	154
Expected restructuring costs	154
Employee Severance Allocated to Selling, General, and Administrative [Member]
Restructuring reserve	74
Restructuring charges	0
Restructuring payments	(65)
Restructuring reserve	9
Restructuring costs incurred	350
Expected restructuring costs	350
Employee Severance Allocated to Research and Development [Member]
Restructuring reserve	0
Restructuring charges	0
Restructuring payments	0
Restructuring reserve	0
Restructuring costs incurred	227
Expected restructuring costs	227
Employee Severance [Member]
Restructuring reserve	74
Restructuring charges	0
Restructuring payments	(65)
Restructuring reserve	9
Restructuring costs incurred	731
Expected restructuring costs	731
Professional Fees and Licenses [Member]
Restructuring reserve	0
Restructuring charges	0
Restructuring payments	0
Restructuring reserve	0
Restructuring costs incurred	28
Expected restructuring costs	$ 28

Note 4 - Operating Leases

3 Months Ended

Apr. 30, 2024

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

NOTE 4 — OPERATING LEASES

We determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate for the expected remaining lease term at commencement date for new and existing leases in determining the present value of future lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has moved to a virtual office model and does not have a physical office space. Membership agreements and daily space rentals are leveraged by the Company when groups need to meet in person with the costs expensed as incurred. For the three months ended April 30, 2024 and 2023, the Company recorded $7,000 and $4,000, respectively, related to such office space rentals.

Alpharetta Office Lease

On October 1, 2021, the Company entered into an agreement with a third-party to sublease its office space in Alpharetta, Georgia. The sublease term was for 18 months, which coincided with the Company’s underlying lease (see below). The Company received $292,000 from the sublessee over the term of the sublease. The sublease did not relieve the Company of its original obligation under the lease, and therefore the Company did not adjust the operating lease right-of-use asset and related liability. The sublease terminated on March 31, 2023. For the three months ended April 30, 2024 and 2023, the Company recorded $0 and $32,000, respectively, as other income related to the sublease.

The Company entered into a lease for office space in Alpharetta, Georgia, on March 1, 2020. The lease terminated on March 31, 2023. At inception, the Company recorded a right-of use asset of $540,000, and related current and long-term operating lease obligation in the accompanying consolidated balance sheet. The Company used a discount rate of 6.5% to determine the lease liability. For the three months ended April 30, 2024 and 2023, the Company had lease operating costs of approximately $0 and $32,000, respectively.

Suwanee Office Lease

Upon acquiring Avelead on August 16, 2021 (refer to Note 3 – Business Combination), the Company assumed an operating lease agreement for the corporate office space of Avelead. The lessor is an entity controlled by one of the Sellers and that Seller is a former employee of the Company. The initial 36-month term lease commenced March 1, 2019, and expired on February 28, 2022. The Company previously renewed the lease for an additional 12-month term which expired February 28, 2023, and was not renewed. For the three months ended April 30, 2024 and 2023, the Company recorded rent expense of $0 and $6,000, respectively.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Apr. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	Item 5. OTHER INFORMATION During the three months ended April 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 9 - Related Party Transactions (Tables)

3 Months Ended

Apr. 30, 2024

Notes Tables

Name of Investor	Investment Amount		Warrants Granted
121G, LLC (1)	$	1,000,000		897,436
Matthew Etheridge (2)		1,000,000		921,053
Jonathan R. Phillips (3)		50,000		44,872
The Ferayorni Family Trust (4)		500,000		448,718

Note 9 - Related Party Transactions (Details Textual) - USD ($)

3 Months Ended

Feb. 07, 2024

Feb. 06, 2024

Apr. 30, 2024

Apr. 30, 2023

Feb. 01, 2024

Stock Issued During Period, Value, New Issues

$ 770,000

Unsecured Subordinated Promissory Notes [Member]

Debt Instrument, Face Amount

4,400,000

Securities Purchase Agreement February 2024 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

4,016,025

Securities Purchase Agreement February 2024 [Member] | Unsecured Subordinated Promissory Notes [Member]

Debt Instrument, Face Amount

$ 4,400,000

Matthew Etheridge [Member]

^[1]

$ 1,000,000

Matthew Etheridge [Member] | Private Placement [Member]

Stock Issued During Period, Shares, New Issues (in shares)

263,158

Shares Issued, Price Per Share (in dollars per share)

$ 0.38

Stock Issued During Period, Value, New Issues

$ 100,000

Rent Expense [Member] | Former Employee of Avelead [Member]

$ 0

$ 6,000

[1]	Mr. Etheridge became a member of the Company’s Board of Directors subsequent to the closing of the Debt Private Placement.

Note 2 - Summary of Significant Accounting Policies 1 (Details Textual)				3 Months Ended
	Mar. 27, 2024 USD ($)	Oct. 16, 2023 USD ($)	Nov. 29, 2022	Apr. 30, 2024 USD ($)	Apr. 30, 2024 USD ($) shares	Apr. 30, 2023 USD ($) shares	Feb. 07, 2024 USD ($)	Feb. 01, 2024 USD ($)	Jan. 31, 2024 USD ($)
Business Combination, Acquisition Related Costs						$ 35,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ 159,000
Fair Value Adjustment of Warrants				$ (135,000)
Business Combination, Contingent Consideration, Liability, Current				817,000	$ 817,000				$ 1,794,000
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]			Prime Rate [Member]		Prime Rate [Member]
Contract with Customer, Liability, Revenue Recognized					$ 2,831,000
Revenue, Remaining Performance Obligation, Amount				29,143,000	29,143,000
Deferred Costs				65,000	65,000				77,000
Accumulated Amortization of Other Deferred Costs				123,000	123,000				102,000
Amortization of Deferred Charges					20,000	18,000
Deferred Commission Costs Paid and Payable				1,321,000	1,321,000				1,461,000
Amortization of Deferred Sales Commissions					140,000	129,000
Share-Based Payment Arrangement, Expense					$ 499,000	$ 572,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) \| shares					2,687,471	2,655,831
Restructuring and Related Cost, Number of Positions Eliminated		26
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent		24.00%
Restructuring Costs		$ 759,000				$ 0
Stock Issued					$ 30,000	$ 23,000
Professional Fees, Noncash					$ 4,000
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) \| shares					66,000	628,958
Restricted Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) \| shares					2,687,471	2,655,831
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) \| shares					4,016,025
Common Stock Warrant [Member]
Derivative Liability							$ 881,000	$ 881,000
Derivative, Gain (Loss) on Derivative, Net					$ 135,000
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) \| shares					1,015,000	1,085,000
Restricted Stock [Member] \| Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) \| shares					200,000	0
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Payment Arrangement, Expense					$ 30,000	$ 23,000
Term Loan and Revolving Line of Credit [Member]
Debt Instrument, Basis Spread on Variable Rate					1.50%
Debt Instrument, Basis Rate Floor					3.25%
Debt Instrument, Increase (Decrease) in Basis Spread on Variable Rate					0.50%
Debt Instrument, Fair Value Disclosure				8,560,000	$ 8,560,000				8,807,000
Debt Instrument, Unamortized Discount				190,000	190,000				193,000
Debt Issuance Costs, Net				61,000	61,000				$ 69,000
Unsecured Subordinated Promissory Notes [Member]
Debt Instrument, Fair Value Disclosure				3,538,000	3,538,000
Debt Instrument, Unamortized Discount				862,000	862,000
Debt Issuance Costs, Net				167,000	167,000
Avelead Acquisition [Member]
Business Combination, Contingent Consideration, Liability, Current				$ 817,000	817,000
Avelead Acquisition [Member] \| Common Stock [Member] \| Second Earnout [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable					690,000
Avelead Acquisition [Member] \| Warrant 1 [Member] \| Second Earnout [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable					$ 881,000
Measurement Input, Exercise Price 1 [Member]
Warrants and Rights Outstanding, Measurement Input							0.38
Measurement Input, Exercise Price 2 [Member]
Warrants and Rights Outstanding, Measurement Input							0.39
Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input				0.3	0.3		0.34
Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input							48
Measurement Input, Risk Free Interest Rate [Member] \| Minimum [Member]
Warrants and Rights Outstanding, Measurement Input							4
Measurement Input, Risk Free Interest Rate [Member] \| Maximum [Member]
Warrants and Rights Outstanding, Measurement Input							5
Measurement Input, Price Volatility [Member] \| Minimum [Member]
Warrants and Rights Outstanding, Measurement Input							91
Measurement Input, Price Volatility [Member] \| Maximum [Member]
Warrants and Rights Outstanding, Measurement Input							92

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Net loss	$ (2,739,000)	$ (2,901,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,120,000	1,059,000
Accrued interest expense – notes payable	152,000	0
Valuation adjustments	24,000	(364,000)
Benefit for deferred income taxes	0	39,000
Share-based compensation expense	499,000	572,000
Changes in assets and liabilities:
Accounts and contract receivables	17,000	3,900,000
Other assets	(100,000)	(15,000)
Accounts payable	(161,000)	(327,000)
Accrued expenses and other liabilities	(262,000)	(795,000)
Deferred revenue	251,000	(1,042,000)
Net cash used in operating activities	(1,199,000)	126,000
Cash flows from investing activities:
Purchases of property and equipment	0	(29,000)
Capitalization of software development costs	(232,000)	(404,000)
Net cash used in investing activities	(232,000)	(433,000)
Cash flows from financing activities:
Repayment of bank term loan	(250,000)	(125,000)
Repayment of line of credit	(1,500,000)	0
Proceeds from issuance of common stock	100,000	0
Proceeds from notes payable	4,400,000	0
Payments of acquisition earnout liabilities	(447,000)	0
Payments for deferred financing costs	(16,000)	0
Payments related to settlement of employee share-based awards	(67,000)	(179,000)
Net cash (used in) provided by financing activities	2,220,000	(304,000)
Net (decrease) increase in cash and cash equivalents	789,000	(611,000)
Cash and cash equivalents at beginning of period	3,190,000	6,598,000
Cash and cash equivalents at end of period	$ 3,979,000	$ 5,987,000

Note 2 - Summary of Significant Accounting Policies - Acquisition Earnout Liability Rollforward (Details)	3 Months Ended
	Apr. 30, 2024 USD ($)
Beginning balance	$ 1,794,000
Settlement – common stock	(690,000)
Settlement – cash	(447,000)
Unrealized loss	159,000
Transfer out	(817,000)
Ending balance	0
Amount of unrealized loss for the period included in income relating to the acquisition earnout liability at the end of the period	$ (159,000)

Note 2 - Summary of Significant Accounting Policies

3 Months Ended

Apr. 30, 2024

Notes to Financial Statements

Significant Accounting Policies [Text Block]

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Our significant accounting policies are presented in “Note 2 – Significant Accounting Policies” in the Annual Report on Form 10-K for fiscal year 2023. Users of financial information for interim periods are encouraged to refer to the notes to the consolidated financial statements contained in the Annual Report on Form 10-K when reviewing interim financial results.

Use of Estimates

Reclassification

Fair Value of Financial Instruments

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

The table below provides information on the fair value of our liabilities:

			Quoted		Significant
			Prices in		Other		Significant
			Active		Observable		Unobservable
	*Total Fair*		*Markets*		*Inputs*		*Inputs*
	*Value*		*(Level 1)*		*(Level 2)*		*(Level 3)*
At January 31, 2024
Acquisition earnout liability (1)	$	1,794,000	$	—	$	—	$	1,794,000
At April 30, 2024
Warrants - common stock (2)	$	746,000	$	—	$	746,000	$	—

(1)

(2)

The table below provides the Level 3 roll-forward on the fair value of our acquisition earnout liability for the three months ended April 30, 2024:

	3 months ended
	04/30/2024
Beginning balance	$	1,794,000
Settlement – common stock		(690,000	)
Settlement – cash		(447,000	)
Unrealized loss		159,000
Transfer out		(817,000	)
Ending balance	$	—
Amount of unrealized loss for the period included in income relating to the acquisition earnout liability at the end of the period	$	(159,000	)

Revenue Recognition

Disaggregation of Revenue

The following table provides information about disaggregated revenue by type and nature of revenue stream:

	Three Months Ended
	April 30, 2024		April 30, 2023
Over time revenue	$	4,195,000	$	5,258,000
Point in time revenue		135,000		74,000
Total revenue	$	4,330,000	$	5,332,000

Contract Receivables and Deferred Revenues

Deferred costs (costs to fulfill a contract and contract acquisition costs)

Allowance for Credit Losses

		January 31, 2024				CECL Adoption				Provision adjustments				Write-offs & Recoveries				April 30, 2024
Allowance for credit losses		$	86,000			$	—			$	—			$	31,000			$	117,000

		January 31, 2023				CECL Adoption				Provision adjustments				Write-offs & Recoveries				April 30, 2023
Allowance for credit losses		$	132,000			$	(36,000	)		$	—			$	—			$	96,000

Equity Awards

Warrants

Income Taxes

Net Loss Per Common Share

The Company presents basic and diluted earnings per share (“EPS”) data for the Company’s common stock.

The following is the calculation of the basic and diluted net loss per share of common stock for the three months ended April 30, 2024 and 2023:

	Three Months Ended
	April 30, 2024			April 30, 2023
Basic and diluted loss per share:
Net loss	$	(2,739,000	)	$	(2,901,000	)
Basic and diluted net loss per share of common stock	$	(0.05	)	$	(0.05	)
Weighted average shares outstanding – basic and diluted (1)(2)		58,224,090			55,970,880

(1)	Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of April 30, 2024 and 2023, there were 2,687,471 and 2,655,831 unvested restricted shares of common stock outstanding, respectively.

(2)	Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three months ended April 30, 2024, diluted earnings per share excludes 66,000 outstanding stock options, 2,687,471 unvested restricted shares of common stock, and 4,016,025 shares of common stock issuable through the exercise of warrants. For the three months ended April 30, 2023, diluted earnings per share excludes 628,958 outstanding stock options and 2,655,831 unvested restricted shares of common stock.

Restructuring

On October 16, 2023, the Company announced it was executing a strategic restructuring (the "Strategic Restructuring") designed to reduce expenses while maintaining the Company’s ability to expand its SaaS business. The Strategic Restructuring initiatives included a reduction in force, resulting in the termination of 26 employees, or approximately 24% of the Company’s workforce. To execute the Strategic Restructuring, the Company incurred one-time restructuring costs associated with the workforce reduction of $759,000, and the Company has recognized all expenses associated with the Strategic Restructuring as of the end of fiscal 2023. The costs pertain to severance and other employee termination-related costs and various professional fees the Company required to assist with execution of the Strategic Restructuring. For the period ended April 30, 2023, there were no costs incurred or accrued related to the strategic restructuring. The following is a reconciliation of the Strategic Restructuring liability reflected on the Company’s condensed consolidated balance sheet under “accrued expenses.”

	(in thousands)
										As of April 30, 2024
	*Accrued Balance as of*		*2024*		*2024*			*Accrued Balance as of*		*Total Costs*		*Total*
	*January 31, 2024*		*Expenses to Date*		*Cash Payments*			*April 30, 2024*		*Incurred to Date*		*Expected Costs*
Severance expense
Cost of sales	$	—	$	—	$	—		$	—	$	154	$	154
Selling, general, and administrative		74		—		(65	)		9		350		350
Research and development		—		—		—			—		227		227
Total severance expense	$	74	$	—	$	(65	)	$	9	$	731	$	731
Professional fees		—		—		—			—		28		28
Total	$	74	$	—	$	(65	)	$	9	$	759	$	759

Non-Cash Items

Recent Accounting Pronouncements Not Yet Adopted

Note 3 - Business Combination

3 Months Ended

Apr. 30, 2024

Notes to Financial Statements

Business Combination Disclosure [Text Block]

NOTE 3 — BUSINESS COMBINATION

Avelead Acquisition

The Company acquired all the equity interests of Avelead Consulting, LLC (“Avelead”) as part of the Company’s strategic expansion into the acute-care health care revenue cycle management industry (the “Transaction”). The Transaction was completed on August 16, 2021.

As of January 31, 2024, the estimated aggregate value of the second year earnout consideration was $1,794,000. On March 27, 2024, the Company issued 1,589,386 unregistered securities in the form of restricted common stock, par value $0.01 per share, with respect to the second year earnout consideration. As of April 30, 2024, the Company had made cash payments of $447,000 related to the second year earnout consideration with periodic payments to be made through October 31, 2024. The remaining cash liability is reflected on the Company’s condensed consolidated balance sheet as “acquisition earnout liability” and totaled $817,000 as of April 30, 2024.

Note 9 - Related Party Transactions - Schedule of Related Party Transactions (Details)

Feb. 07, 2024

USD ($)

Wyche Tee Green III [Member]

Related party transactions | $

$ 1,000,000

^[1]

Wyche Tee Green III [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]

Warrants Granted (in shares) | shares

897,436

^[1]

Matthew Etheridge [Member]

Related party transactions | $

$ 1,000,000

^[2]

Matthew Etheridge [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]

Warrants Granted (in shares) | shares

921,053

^[2]

Jonathan R Phillips [Member]

Related party transactions | $

$ 50,000

^[3]

Jonathan R Phillips [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]

Warrants Granted (in shares) | shares

44,872

^[3]

Justin J Ferayorni [Member]

Related party transactions | $

$ 500,000

^[4]

Justin J Ferayorni [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]

Warrants Granted (in shares) | shares

448,718

^[4]

[1]	The securities held in the account of 121G, LLC (“121G”) may be deemed to be beneficially owned by Wyche “Tee” Green, III, the managing member of 121G. Mr. Green serves as Executive Chairman of the Company and is a member of the Company’s Board of Directors.
[2]	Mr. Etheridge became a member of the Company’s Board of Directors subsequent to the closing of the Debt Private Placement.
[3]	Mr. Phillips is a member of the Company’s Board of Directors.
[4]	The securities held in the account of The Ferayorni Family Trust may be deemed to be beneficially owned by Justin J. Ferayorni as co-trustee of The Ferayorni Family Trust. Mr. Ferayorni is a member of the Company’s board of directors.

Note 2 - Summary of Significant Accounting Policies - Accounting Standards Update (Details) - USD ($)	3 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Allowance for credit losses	$ 86,000	$ 132,000
Allowance for credit losses, provision	0	0
Allowance for credit losses, writeoffs	31,000	0
Allowance for credit losses	117,000	96,000
Cumulative Effect, Period of Adoption, Adjustment [Member] \| Accounting Standards Update 2016-13 [Member]
Allowance for credit losses	$ 0	$ (36,000)

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Apr. 30, 2024	Jun. 10, 2024
Document Information [Line Items]
Entity Central Index Key	0001008586
Entity Registrant Name	STREAMLINE HEALTH SOLUTIONS INC.
Amendment Flag	false
Current Fiscal Year End Date	--01-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 30, 2024
Document Transition Report	false
Entity File Number	000-28132
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	31-1455414
Entity Address, Address Line One	2400 Old Milton Pkwy., Box 1353
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30009
City Area Code	888
Local Phone Number	997-8732
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	STRM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		62,030,026

Note 7 - Equity (Details Textual) - USD ($)					3 Months Ended
Note 7 - Equity (Details Textual) - USD ($)	May 24, 2024	Feb. 06, 2024	Jun. 28, 2023	Jun. 15, 2023	Apr. 30, 2024	Jun. 07, 2022
The 2013 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)				1,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				11,223,246		10,223,246
180 Consulting [Member]
Stock Issued During Period, Shares, New Issues (in shares)			394,127
180 Consulting [Member] \| Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	564,707
Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares)		263,158
Sale of Stock, Price Per Share (in dollars per share)		$ 0.38
Sale of Stock, Consideration Received on Transaction		$ 100,000
Net Proceeds from Issuance of Private Placement					$ 77,000
Proceeds from Issuance of Private Placement					81,000
Payments of Stock Issuance Costs					$ 4,000

Note 2 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Apr. 30, 2024

Notes Tables

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

			Quoted		Significant
			Prices in		Other		Significant
			Active		Observable		Unobservable
	*Total Fair*		*Markets*		*Inputs*		*Inputs*
	*Value*		*(Level 1)*		*(Level 2)*		*(Level 3)*
At January 31, 2024
Acquisition earnout liability (1)	$	1,794,000	$	—	$	—	$	1,794,000
At April 30, 2024
Warrants - common stock (2)	$	746,000	$	—	$	746,000	$	—

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	3 months ended
	04/30/2024
Beginning balance	$	1,794,000
Settlement – common stock		(690,000	)
Settlement – cash		(447,000	)
Unrealized loss		159,000
Transfer out		(817,000	)
Ending balance	$	—
Amount of unrealized loss for the period included in income relating to the acquisition earnout liability at the end of the period	$	(159,000	)

Disaggregation of Revenue [Table Text Block]

	Three Months Ended
	April 30, 2024		April 30, 2023
Over time revenue	$	4,195,000	$	5,258,000
Point in time revenue		135,000		74,000
Total revenue	$	4,330,000	$	5,332,000

Accounting Standards Update and Change in Accounting Principle [Table Text Block]

		January 31, 2024				CECL Adoption				Provision adjustments				Write-offs & Recoveries				April 30, 2024
Allowance for credit losses		$	86,000			$	—			$	—			$	31,000			$	117,000

		January 31, 2023				CECL Adoption				Provision adjustments				Write-offs & Recoveries				April 30, 2023
Allowance for credit losses		$	132,000			$	(36,000	)		$	—			$	—			$	96,000

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended
	April 30, 2024			April 30, 2023
Basic and diluted loss per share:
Net loss	$	(2,739,000	)	$	(2,901,000	)
Basic and diluted net loss per share of common stock	$	(0.05	)	$	(0.05	)
Weighted average shares outstanding – basic and diluted (1)(2)		58,224,090			55,970,880

Restructuring and Related Costs [Table Text Block]

	(in thousands)
										As of April 30, 2024
	*Accrued Balance as of*		*2024*		*2024*			*Accrued Balance as of*		*Total Costs*		*Total*
	*January 31, 2024*		*Expenses to Date*		*Cash Payments*			*April 30, 2024*		*Incurred to Date*		*Expected Costs*
Severance expense
Cost of sales	$	—	$	—	$	—		$	—	$	154	$	154
Selling, general, and administrative		74		—		(65	)		9		350		350
Research and development		—		—		—			—		227		227
Total severance expense	$	74	$	—	$	(65	)	$	9	$	731	$	731
Professional fees		—		—		—			—		28		28
Total	$	74	$	—	$	(65	)	$	9	$	759	$	759

Note 2 - Summary of Significant Accounting Policies 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-05-01	Apr. 30, 2024
Revenue, Remaining Performance Obligation, Percentage	45.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month)	12 months

Note 5 - Debt

3 Months Ended

Apr. 30, 2024

Notes to Financial Statements

Debt Disclosure [Text Block]

NOTE 5 — DEBT

Outstanding principal balances consisted of the following at April 30, 2024:

	April 30, 2024			January 31, 2024
Term loan	$	8,750,000		$	9,000,000
Financing cost payable		150,000			135,000
Less: Deferred financing cost		(61,000	)		(69,000	)
Total		8,839,000			9,066,000
Less: Current portion of term loan		(1,750,000	)		(1,500,000	)
Non-current portion of term loan	$	7,089,000		$	7,566,000

	April 30, 2024			January 31, 2024
Notes payable	$	4,552,000		$	—
Less: Discount on notes payable		(796,000	)		—
Less: Deferred financing costs		(169,000	)		—
Total		3,587,000			—
Less: Current portion of notes payable		—			—
Non-current portion of notes payable	$	3,587,000		$	—

Term Loan and Revolving Line of Credit

On November 29, 2022, the Company executed a Second Modification to Second Amended and Restated Loan Agreement (the “Second Modification”). The Second Modification includes an expansion of the Company’s total borrowing to include a $2,000,000 non-formula revolving line of credit. The revolving line of credit will be co-terminus with the term loan and matures on August 26, 2026. There are no requirements to draw on the line of credit. Amounts outstanding under the line of credit portion of the Second Amended and Restated Loan Agreement bear interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus 1.5%, with a Prime “floor” rate of 3.25%. The Second Modification amended certain financial covenants in the Second Amended and Restated Loan Agreement.

Under the Second Amended and Restated Loan Agreement, the Company has a term loan facility with an initial maximum principal amount of $10,000,000. Amounts outstanding under the Second Amended and Restated Loan Agreement bear interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus 1.5%, with a Prime “floor” rate of 3.25%. The Second Amended and Restated Loan Agreement has a five-year term, and the maximum principal amount was advanced in a single-cash advance on or about the original closing date ( August 2021). Interest is due monthly, and the Company shall make monthly interest-only payments through the one-year anniversary of the original closing date. Under the Second Amended and Restated Loan Agreement, principal repayments are required of $500,000 in the second year, $1,000,000 in the third year, $2,000,000 in the fourth year, and $3,000,000 in the fifth year with the remaining outstanding principal balance and all accrued but unpaid interest due in full on the maturity date. The Second Amended and Restated Loan Agreement may also require early repayments if certain conditions are met.

The Company executed a Third Modification and Waiver to Second Amended and Restated Loan Agreement (the “Third Modification”) and a Fourth Modification to Second Amended and Restated Loan Agreement (the “Fourth Modification”) on February 7, 2024 and April 5, 2024, respectively (collectively, the “Third and Fourth Modifications”). The Third and Fourth Modifications reestablished the customary financial covenants for the Second Amended and Restated Loan Agreement as follows:

●

Minimum Adjusted EBITDA. Commencing with the quarter ending January 31, 2024, the Company shall maintain Adjusted EBITDA, measured on a quarterly basis as of the last day of each fiscal quarter, in an amount not less than the amounts (or, in the case of amounts set forth in parentheses, no worse than the amounts) set forth under the heading “Minimum Adjusted EBITDA” as of, and for each of the dates appearing adjacent to such “Minimum Adjusted EBITDA.”

	Minimum
Quarter Ending	Adjusted EBITDA
January 31, 2024	$	(5,750,000	)
April 30, 2024		(4,560,000	)
July 31, 2024		(2,960,000	)
October 31, 2024		(1,500,000	)
January 31, 2025		430,000

●

Maximum ARR Net Leverage Ratio. The Company's ARR Net Leverage Ratio, measured on a quarterly basis as of the last day of each fiscal quarter, shall not be greater than the amount set forth under the heading “Maximum ARR Net Leverage Ratio” as of, and for each of the dates appearing adjacent to such “Maximum ARR Net Leverage Ratio.”

	Maximum
	ARR Net Leverage
Quarter Ending	Ratio
April 30, 2024	0.50	to	1.00
July 31, 2024	0.45	to	1.00
October 31, 2024	0.40	to	1.00
January 31, 2025	0.35	to	1.00

●

Maximum Debt to Adjusted EBITDA Ratio. Commencing with the quarter ending April 30, 2025, the Company's Maximum Debt to Adjusted EBITDA Ratio, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended, shall not be greater than the amount set forth under the heading “Maximum Debt to Adjusted EBITDA Ratio” as of, and for each of the dates appearing adjacent to such “Maximum Debt to Adjusted EBITDA Ratio.”

	Maximum
	Debt to Adjusted
	EBITDA
Quarter Ending	Ratio
April 30, 2025	3.50	to	1.00
July 31, 2025	3.00	to	1.00
October 31, 2025	2.50	to	1.00
January 31, 2026 and on the last day of each quarter thereafter	2.00	to	1.00

●

Fixed Charge Coverage Ratio. Commencing with the quarter ending April 30, 2025, the Company shall maintain a Fixed Charge Coverage Ratio of not less than 1.20 to 1.00, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended.

The Second Amended and Restated Loan Agreement also includes customary negative covenants, subject to exceptions, which limit transfers, capital expenditures, indebtedness, certain liens, investments, acquisitions, dispositions of assets, restricted payments, and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including cross defaults and a change of control default. The line of credit also is subject to customary prepayment requirements. Substantially all the assets of the Company are collateralized by the Second Amended and Restated Loan Agreement. As of April 30, 2024, the Company was in compliance with the Second Amended and Restated Loan Agreement covenants.

The Company records costs related to the maintenance of the Second Amended and Restated Loan Agreement as deferred financing costs, net of the term loan. These deferred financing costs are being amortized over the remaining term of the loan. The Company has incurred $250,000 in financing costs which become payable at the earlier of the term date of the loan, or pre-payment. These costs are being accreted, through interest expense, to the full value of the $250,000 over the remaining term of the loan.

Debt Private Placement

On February 1, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors, including certain directors and officers of the Company (collectively, the “Investors”), pursuant to which the Company agreed to sell to the Investors unsecured subordinated promissory notes (the “Notes”) in the aggregate principal amount of $4.4 million and warrants (the “Warrants”) to purchase up to an aggregate of 4,016,025 shares of the Company’s common stock (the “Common Stock”) in a private placement (the “Debt Private Placement”). The closing of the Debt Private Placement occurred on February 7, 2024 (the “Closing Date”).

Notes Payable

The Notes bear interest at a rate of 15% per annum and mature on August 7, 2026 (the “Maturity Date”). All accrued and unpaid interest on the Notes will be capitalized and added to the outstanding principal balance of the Notes and will be payable in cash on the Maturity Date. The Company may redeem the Notes, in whole or in part, prior to the Maturity Date without any premium or penalty. In the event the Company prepays any portion of the then outstanding principal balance of the Notes on or before the twelve (12) month anniversary of the Closing Date, in addition to such prepayment of the principal balance, the Company must pay to the Investors a prepayment fee (in accordance with the each Investor’s pro-rata share of the Notes) in an amount equal to the amount of interest that would have accrued but for the prepayment from the date of such prepayment through such twelve (12) month anniversary of the Closing Date.

The Notes also include customary negative covenants, subject to exceptions, which limit dispositions of assets and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including cross defaults and a change of control default.

The rights of each Investor to receive payments under the Notes are subordinate to the rights of Western Alliance Bank (“WAB”), pursuant to a subordination agreement which the Investors entered into with WAB concurrently with the Debt Private Placement.

The Company allocated the original total proceeds at inception from the Debt Private Placement and Common Stock Private Placement (refer to Note 7 – Equity) across the securities issued in connection with the offerings. The Company has recorded the Notes at a relevant residual fair value of $3,538,000, consisting of the $4,400,000 face value of the notes and $862,000 discount. The Company allocated $183,000 in issuance costs. The discount is being accreted and the financing costs amortized as interest expense over the term of the Notes.

Warrants

The Warrants have an exercise price of $0.38 (except for Warrants issued to the Company’s directors and officers which have an exercise price of $0.39), are immediately exercisable, and will expire on the fourth anniversary of the Closing Date. The Warrants are subject to customary adjustments for certain transactions affecting the Company’s capitalization. The terms of the Warrants preclude a holder thereof from exercising such holder’s Warrants, and the Company from giving effect to such exercise, if after giving effect to the issuance of Common Stock upon such exercise, the holder (together with the holder’s affiliates and any other persons acting as a group together with the holder or any of the holder’s affiliates) would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Common Stock upon such exercise.

The Notes and the Warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the Common Stock underlying the Warrants, were "restricted securities" under the Securities Act or applicable state securities laws. Accordingly, the Notes, the Warrants and the Common Stock underlying the Warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements and in accordance with applicable state securities laws. The securities were offered and sold to “accredited investors” as that term is defined in Rule 501(a) under the Securities Act.

The Warrants contain a registration rights provision for the Company to provide the Warrant holder with registered Common Stock upon their exercise of a Warrant. If the Company is not able to deliver registered Common Stock for exercised Warrants that results in the Warrant holder acquiring registered Common Stock, then the Warrant holder has the discretion to request the Company remit cash compensation up to the corresponding purchase price. Accordingly, the Company determined the feature required liability accounting treatment. On May 7, 2024, the Company filed a Registration Statement on Form S-3 (Registration No. 333-279190), as amended by that certain Pre-Effective Amendment No. 1 to Form S-3 filed on May 24, 2024, for purpose of registering for resale 4,016,025 shares of common stock underlying the Warrants. The Registration Statement was declared effective by the SEC on June 10, 2024.

The Company allocated the total proceeds from the Debt Private Placement and Common Stock Private Placement (refer to Note 7 – Equity) across the securities issued in connection with offerings. The Company recorded an initial liability of $881,000 for the Warrants at fair value using a Black-Scholes model. For the three-month period ended April 30, 2024, the Company immediately recognized $46,000 in issuance costs as expense related to the agreements for the Warrants.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Note 1 - Basis of Presentation (Details Textual)	3 Months Ended
Note 1 - Basis of Presentation (Details Textual)	Apr. 30, 2024
Number of Operating Segments	1
Number of Reportable Segments	1

Note 7 - Equity

3 Months Ended

Apr. 30, 2024

Notes to Financial Statements

Equity [Text Block]

NOTE 7 — EQUITY

Common Stock Private Placement

On February 6, 2024, the Company completed the sale of 263,158 shares of the Company’s common stock to an accredited investor at a purchase price of $0.38 per share for an aggregate purchase price of $100,000 (the “Common Stock Private Placement”).

The common stock described above was offered in a private placement under Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and has not been registered under the Securities Act or applicable state securities laws. Accordingly, such common stock may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements and in accordance with applicable state securities laws. The Common Stock was offered and sold to an “accredited investor” as that term is defined in Rule 501(a) under the Securities Act.

The Company allocated the total proceeds of the Common Stock Private Placement across the underlying components. As a result, $77,000 of net proceeds, comprised of $81,000 of the proceeds less $4,000 of issuance costs, was recorded for the Common Stock Private Placement as equity in the three-month period ended April 30, 2024.

Registration of Shares Issued to 180 Consulting

On June 28, 2023, the Company filed a Registration Statement on Form S-3 (Registration No. 333-272993) for purpose of registering for resale 394,127 shares of common stock issued to 180 Consulting, LLC (“180 Consulting”). The Registration Statement was declared effective by the SEC on July 10, 2023.

On May 7, 2024, the Company filed a Registration Statement on Form S-3 (Registration No. 333-279190), as amended by that certain Pre-Effective Amendment No. 1 to Form S-3 filed on May 24, 2024, for purpose of registering for resale 564,707 shares of common stock issued to 180 Consulting. The Registration Statement was declared effective by the SEC on June 10, 2024.

Authorized Shares Increase

At the Annual Meeting of Stockholders held on June 15, 2023, the Company’s stockholders approved an amendment to the Streamline Health Solutions, Inc. Third Amended and Restated 2013 Stock Incentive Plan to increase the available number of shares of the Company’s common stock authorized for issuance thereunder by 1,000,000 shares, from 10,223,246 shares to 11,223,246 shares.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Note 5 - Debt - Schedule of Debt to APR Ratio (Details)	3 Months Ended
Note 5 - Debt - Schedule of Debt to APR Ratio (Details)	Jan. 31, 2025	Oct. 31, 2024	Jul. 31, 2024	Apr. 30, 2024
Maximum [Member]
Debt to APR ratio				0.5
Maximum [Member] \| Forecast [Member]
Debt to APR ratio	0.35	0.4	0.45
Minimum [Member]
Debt to APR ratio				1
Minimum [Member] \| Forecast [Member]
Debt to APR ratio	1	1	1